|
reviously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Within two years of the founding of the company (1998), Celera announced the first successful sequencing of the human genome. Peter helped launch Celera as a publicly traded entity in 1999, and it became a leading force within the biotechnology industry. Peter led Celera’s expansion into drug discovery and development, forging strategic alliances with technology companies and leading the acquisition of Axys Pharmaceuticals.
Prior to Celera, Peter held senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. During his tenure, he expanded the life science business units through a series of licensing agreements, partnerships and acquisitions including: Applied Biosystems, Tropix, Molecular Informatics, PerSeptive Biosystems, and Genscope. Also during this time, Peter co-founded Celera Genomics with Dr. J. Craig Venter and the Applera Corporation management team. Additional managerial roles included Executive Vice President of the Applied Biosystems Division of Perkin-Elmer.
Peter currently serves on the Boards of Atlas Venture portfolio companies, Archemix, Aureon Laboratories, Helicos Biosciences, InfaCare Pharmaceuticals, LAB International, Vitae Pharmaceuticals and Zafgen. He is Chairman of the board at Momenta Pharmaceuticals (NASDAQ: MNTA), Ivrea Pharmaceuticals and Stromedix. He is also a board member at former Atlas Venture portfolio company Alnylam (NASDAQ: ALNY).
Peter is currently the Vice Chairman of the Advisory Council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University and is President of the Autism Consortium, a non-profit institution.
Peter received his Bachelor of Science in Chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Ph.D. in Analytical Chemistry from Northeastern University. He also completed Harvard Business School’s Management Development Program.
Investment Sector : Life Sciences
Boards :
Archemix, Aureon Laboratories, InfaCare Pharmaceuticals, IVREA Pharmaceuticals, LAB International, Momenta, Stromedix, Vitae Pharmaceuticals, Zafgen, Helicos BioSciences
In the News:
Helicos BioSciences to Ring NASDAQ Closing Bell on July 2, 2007
Helicos BioSciences Announces Commencement of Commercial Manufacturing
LAB International Licenses Fentanyl TAIFUN to Janssen Pharmaceutica NV for Europe
Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch
LAB International to Hold Its Annual General Meeting Of Shareholders June 22, 2007 In Montreal
Archemix and Takeda to Enter into Collaboration for Discovery and Development of Aptamer Therapeutics
Momenta Pharmaceuticals to Present At the Sixth Annual Needham Biotechnology & Medical Technology Conference
Archemix and Merck KGaA Sign Strategic Alliance
Archemix Announces Completion of Phase 1 Trial of ARC1779
Archemix Announces Completion of Phase 1 Trial of ARC1779
Dr. Patrice Milos Joins Helicos BioSciences as Chief Scientific Officer
FierceBiotech Names Archemix Corp. as One of the Fierce 15" Biotech Companies of 2007
Helicos Biosciences Prices Initial Public Offering
Momenta Pharmaceuticals to Present At the Bank of America Health Care Conference
Momenta Pharmaceuticals to Present At the Citigroup 2007 Healthcare Conference
Momenta Pharmaceuticals Announces Date for 2007 Annual Meeting of Stockholders
Momenta Pharmaceuticals to Present At the Acumen BioFion Rodman & Renshaw 4th Annual Global Healthcare Conference
Momenta Pharmaceuticals Initiates Phase I Clinical Study for M118 Subcutaneous Formulation
Helicos Sets IPO at 5.4 mln Shares, $13-$15 | 